Literature DB >> 15746961

Deep sclerectomy augmented with mitomycin C.

N Anand1, C Atherley.   

Abstract

AIMS: To investigate the comparative efficacy and safety of deep sclerectomy with and without intraoperative mitomycin C (MMC) application for lowering the intraocular pressure (IOP).
METHODS: A total of 71 eyes of 71 consecutive patients who had routine deep sclerectomy (DS), nonaugmented (DS-noMMC) or with mitomycin C (DS-MMC) augmentation (0.2 mg/ml for 2 min) and follow-up of 4 months or more were identified from an ongoing prospective database on glaucoma surgery. Indications for MMC use were the presence of risk factors for subconjunctival scarring and low target IOPs. MMC 0.2 mg/ml was applied in the sub-Tenons space for 2 min.
RESULTS: There were 19 eyes in the DS-noMMC group and 52 eyes in the DS-MMC group. In 11 eyes (15.5%), the procedure was complicated by intraoperative perforation of the trabeculo-Descemet's window. Eyes in the DS-MMC group had significantly lower IOPs (MANOVA, P = 0.04). Kaplan-Meier survival curve analysis showed that the probability of maintaining IOP below target IOP level, below 18 mmHg and below 14 mmHg at 1 year was 51, 67, and 35% for the DS-noMMC group and 80, 86, and 74% for the DS-MMC group. The survival rates of the DS-MMC group were not statistically significant (P = 0.06) when the success criterion was maintaining an IOP less than 18 mmHg but were significant for the other criteria, namely IOP less than target levels (P = 0.03) and less than 14 mmHg (P = 0.03). Nd:YAG goniopuncture to lower IOP to target levels was done more frequently in the DS-noMMC group (13 eyes, 81%) than the DS-MMC group (20 eyes, 45%) and this difference was significant (P = 0.03). The prevalence of avascular areas within filtration blebs and transconjunctival oozing of aqueous was significantly higher in the DS-MMC group (P < 0.01).
CONCLUSIONS: The use of intraoperative MMC during deep sclerectomy has a significant effect on the postoperative IOP and increases the probability of achieving target IOPs. However, our current technique of MMC application is associated with a higher incidence of avascular blebs and transconjunctival oozing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15746961     DOI: 10.1038/sj.eye.6701403

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  18 in total

1.  Nd:Yag laser goniopuncture for deep sclerectomy: efficacy and outcomes.

Authors:  Federico Di Matteo; Paolo Bettin; Marina Fiori; Carlo Ciampi; Alessandro Rabiolo; Francesco Bandello
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-30       Impact factor: 3.117

2.  Trabeculectomy combined with deep sclerectomy and scleral flap suture tension adjustment under an anterior chamber maintainer: a new modification of trabeculectomy.

Authors:  Ozcan R Kayikcioglu; Sinan Emre; Ziya Kaya
Journal:  Int Ophthalmol       Date:  2009-12-04       Impact factor: 2.031

3.  Long-term efficacy of deep sclerectomy in Posner-Schlossman syndrome.

Authors:  Fiamma Campana; Guido Caramello; Laura Dallorto; Teresa Rolle
Journal:  BMJ Case Rep       Date:  2015-01-23

4.  Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial.

Authors:  S Cillino; F Di Pace; G Cillino; A Casuccio
Journal:  Eye (Lond)       Date:  2011-09-16       Impact factor: 3.775

5.  Combined cataract and glaucoma surgery with mitomycin C: phacoemulsification-trabeculectomy compared to phacoemulsification-deep sclerectomy.

Authors:  C L Funnell; M Clowes; N Anand
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

6.  Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks.

Authors:  N Anand; S Arora; M Clowes
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

7.  Efficacy and safety of deep sclerectomy in uveitic glaucoma.

Authors:  Saleh A Al Obeidan; Essam A Osman; Abdulrahman M Al-Muammar; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2008-06-19       Impact factor: 2.031

8.  Comparative study of phacoemulsification-subscleral trabeculectomy versus phacoemulsification-deep sclerectomy.

Authors:  Tahrwat H Mokbel; Asaad A Ghanem; Ashraf I Moawad; Ehab M Nafie; Ehab H Nematallah
Journal:  Saudi J Ophthalmol       Date:  2009-10-28

9.  Outcomes of combined phacoemulsification and deep sclerectomy: a 10-year UK single-centre study.

Authors:  K Mercieca; B Shevade; N Anand
Journal:  Eye (Lond)       Date:  2015-09-04       Impact factor: 3.775

10.  Deep sclerectomy and low dose mitomycin C: a randomised prospective trial in west Africa.

Authors:  C Mielke; V K Dawda; N Anand
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.